search
Back to results

Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis (CANHPARI)

Primary Purpose

Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
18F-FDG PET Scan
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Invasive Fungal Disease focused on measuring Positron-Emission Tomography Scan, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Enzyme-Linked Immunospot Assay, Immune Reconstitution Inflammatory Syndrome, Real-Time Polymerase Chain Reaction, beta-1,3-D-glucan, Candida spp., Genetic Susceptibility, Genotype

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Patients' inclusion criteria:

  • Adults aged ≥18 years-old
  • Hospitalized for hematological malignancy or hematopoietic stem cell transplantation
  • Recent (>2months), prolonged (>10 days), profound (>100 PMN/mm3), feverish neutropenia
  • Suspected hepatosplenic candidiasis (typical small nodular lesions on abdominal RMI or CT)

Patients' exclusion criteria:

- hepatosplenic lesions of other proven origin

Patients' non-inclusion criteria:

  • Life expectancy >3 months
  • Pregnancy
  • HIV infection
  • Hepatic biopsy within 3 weeks before 18F-FDG PET scan

Sites / Locations

  • Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants Malades,

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

18F-FDG PET Scan

Arm Description

18F-FDG PET Scan at Day 0 and M3

Outcomes

Primary Outcome Measures

Global response to therapy
Clinical assessment (no fever) and PET scan assessment (intensity of liver and/or spleen lesions)

Secondary Outcome Measures

18F-FDG PET scan and RMI usefulness in initial diagnosis
Comparison between Day 0 and Month 3 exams
Serological and molecular mycological tools assessment
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls. Assessment of a new real-time PCR on serum and hepatic tissue
Serological and molecular mycological tools assessment
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls. Assessment of a new real-time PCR on serum and hepatic tissue
Serological and molecular mycological tools assessment
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls. Assessment of a new real-time PCR on serum and hepatic tissue
Inflammatory cells and mediators
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Inflammatory cells and mediators
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Inflammatory cells and mediators
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Genetic susceptibility
Search for susceptibility genes to candidiasis in comparison with controls

Full Information

First Posted
August 2, 2013
Last Updated
April 27, 2018
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
University of Lausanne Hospitals, University Hospital, Lille, Institut Pasteur, Institut National de la Santé Et de la Recherche Médicale, France
search

1. Study Identification

Unique Protocol Identification Number
NCT01916057
Brief Title
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
Acronym
CANHPARI
Official Title
Multicenter Prospective Pilot Study Investigating Pathophysiology, Diagnostic and Therapeutic Strategies of Hepatosplenic Candidiasis
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
November 19, 2013 (Actual)
Primary Completion Date
June 1, 2017 (Actual)
Study Completion Date
February 28, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
University of Lausanne Hospitals, University Hospital, Lille, Institut Pasteur, Institut National de la Santé Et de la Recherche Médicale, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
Detailed Description
Chronic disseminated candidiasis, often referred to as hepatosplenic candidiasis (HSC), is an infection due to Candida spp. that mainly involves the liver and spleen. HSC occurs mostly in patients with profound and prolonged neutropenia, which is more often seen in patients with hematologic malignancies. Despite an appropriate antifungal prophylaxis, the incidence of HSC in France might be closed to 5% in patients suffering from acute leukemia. Early and adequate diagnosis and treatment of HSC are crucial, as treatment delays can negatively affect the prognosis of the underlying condition. Current guidelines recommend a 6-month duration treatment. Prolonged treatments up to 6 months are frequent, leading to antifungal toxicity and cost increase. Preliminary study by our team has already assessed F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) as a diagnostic tool for HSC. 18F-FDG PET scan could be helpful in the diagnosis, follow-up and therapy strategy of HSC, helping to stop antifungal treatment. Other molecular, immunological and serological tools have to be developed in order to avoid hepatic biopsies. Actually, mycological evidence of infection is found in only 20% of the cases. The pathogenesis of HSC is also not well understood, but it is believed that it may be due to an unbalanced adaptive immune response that leads to an exacerbated inflammatory reaction, resulting in an Immune Reconstitution Inflammatory Syndrome (IRIS). In that context, a better understanding of the disease pathophysiology and of the potential genetic susceptibility could have an impact on therapy strategy. For example, new approaches such as the use of adjuvant high-dose corticosteroids have been shown beneficial. This study is the first step to improve HSC diagnosis and therapy strategy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation, Neutropenia
Keywords
Positron-Emission Tomography Scan, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Enzyme-Linked Immunospot Assay, Immune Reconstitution Inflammatory Syndrome, Real-Time Polymerase Chain Reaction, beta-1,3-D-glucan, Candida spp., Genetic Susceptibility, Genotype

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
18F-FDG PET Scan
Arm Type
Experimental
Arm Description
18F-FDG PET Scan at Day 0 and M3
Intervention Type
Device
Intervention Name(s)
18F-FDG PET Scan
Intervention Description
to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
Primary Outcome Measure Information:
Title
Global response to therapy
Description
Clinical assessment (no fever) and PET scan assessment (intensity of liver and/or spleen lesions)
Time Frame
at month 3
Secondary Outcome Measure Information:
Title
18F-FDG PET scan and RMI usefulness in initial diagnosis
Description
Comparison between Day 0 and Month 3 exams
Time Frame
at month 3
Title
Serological and molecular mycological tools assessment
Description
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls. Assessment of a new real-time PCR on serum and hepatic tissue
Time Frame
at day 0
Title
Serological and molecular mycological tools assessment
Description
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls. Assessment of a new real-time PCR on serum and hepatic tissue
Time Frame
at Month 3
Title
Serological and molecular mycological tools assessment
Description
Measurement of beta-1,3-D-glucans, mannan/anti-mannan, anti-Saccharomyces cerevisiae antibodies in comparison with controls. Assessment of a new real-time PCR on serum and hepatic tissue
Time Frame
at Month 6
Title
Inflammatory cells and mediators
Description
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Time Frame
at day 0
Title
Inflammatory cells and mediators
Description
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Time Frame
at month 3
Title
Inflammatory cells and mediators
Description
Measurement of cytokines and lymphocytes populations on serum and hepatic tissue in comparison with controls
Time Frame
at month 6
Title
Genetic susceptibility
Description
Search for susceptibility genes to candidiasis in comparison with controls
Time Frame
at day 0

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Patients' inclusion criteria: Adults aged ≥18 years-old Hospitalized for hematological malignancy or hematopoietic stem cell transplantation Recent (>2months), prolonged (>10 days), profound (>100 PMN/mm3), feverish neutropenia Suspected hepatosplenic candidiasis (typical small nodular lesions on abdominal RMI or CT) Patients' exclusion criteria: - hepatosplenic lesions of other proven origin Patients' non-inclusion criteria: Life expectancy >3 months Pregnancy HIV infection Hepatic biopsy within 3 weeks before 18F-FDG PET scan
Facility Information:
Facility Name
Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants Malades,
City
Paris
ZIP/Postal Code
75015
Country
France

12. IPD Sharing Statement

Learn more about this trial

Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis

We'll reach out to this number within 24 hrs